The seizures as reported to occur among children with NS appear to share several features with PDS, namely multiple seizure types. However, NS does not represent PDS in its typical form; any relationship between NS and pyridoxine deficiency is only suspected in light of the presence of the deficiency in the population. However, unpublished findings from two investigations undertaken separately in Uganda (2010) and South Sudan (2011) show that deficiency of B6 has been noticed among this population of children (both cases and controls) raises the possibility of a contributory role of B6 deficiency in NS. Since the entire population, including both children with and without NS, appears to be pyridoxine-deficient, the illness cannot be attributed to B6 deficiency alone; however, the possibility that low B6 levels may be a contributory factor remains and therefore a treatment trial with pyridoxine is proposed because PDS is a therapeutic diagnostic consideration in such settings. Because the seizures in children with NS appear to have a gradual onset, and are intermittent with significant interictal periods, intravenous administration of pyridoxine is not necessary and oral supplementation will be most appropriate. B6 treatment is safe. There are few reports of significant side effects of B6 treatment. Apnea, lethargy and hypotonia among infants soon after starting B6 have been reported (3 out of 5 infants by Mikati, et al), but these are rare (29).